In May 2026, JMIR Correspondent Anna Zucker published a News and Perspectives piece in the Journal of Medical Internet Research examining a gap in telehealth-delivered GLP-1 care that gets far less attention than prescribing access does: what happens to a patient's body composition, not just their weight, over the course of treatment.[1] The piece reports on findings from a 2026 scoping review published in Obesity Reviews, which examined 12 clinical trials assessing nutrient intake in patients taking GLP-1 medications.[2]
What the underlying review examined
The scoping review's scope was narrow and specific: among patients taking GLP-1 medications in the 12 reviewed trials, what happened to caloric intake, and what proportion of weight lost was lean tissue versus fat mass. It also tracked how many of the 12 trials involved a registered dietitian in the patient's care.
Why lean mass loss matters clinically
Muscle tissue is metabolically active — it's a meaningful driver of resting energy expenditure — and losing it at a rate that exceeds the natural age-related decline seen in older adults raises functional and metabolic concerns independent of the scale number. One of the 12 reviewed studies specifically identified nutrient inadequacies among participants, and the review's authors noted that very low caloric intake without accompanying clinical guidance may increase the risk of inadequate protein intake, poor dietary quality, and micronutrient deficiencies.[2]
Only three of twelve reviewed trials involved a registered dietitian in the patient's care pathway.
The dietitian gap specifically
The involvement rate — 3 of 12 trials — is the review's most direct policy-relevant finding. GLP-1 medications work primarily by suppressing appetite and slowing gastric emptying; they don't inherently protect muscle tissue during the resulting caloric deficit. Preserving lean mass during GLP-1-driven weight loss generally requires deliberate intervention — adequate protein intake and resistance training — that a prescribing platform doesn't automatically provide unless it's built into the program.
A scoping review, not a meta-analysis
It's worth being precise about the study type. A scoping review maps the existing literature on a question rather than statistically pooling results the way a meta-analysis does. That makes it well-suited to identifying a gap — like limited dietitian involvement — but it doesn't produce a single pooled effect size the way a meta-analysis would for, say, average lean mass loss across a larger combined patient population.
What this doesn't establish
It doesn't isolate telehealth specifically as the cause. The 12 reviewed trials weren't necessarily telehealth-delivered — the lean mass finding reflects GLP-1 treatment broadly, with the telehealth-specific concern being that dietitian involvement is even less likely to be built into a fast-scaling, low-touch telehealth model than into a clinical trial protocol.
Twelve trials is a modest evidence base. The finding is directionally consistent and clinically plausible given known GLP-1 mechanisms, but a scoping review of 12 studies is not the same evidentiary weight as a large, adequately powered randomized trial designed specifically to measure body composition outcomes.
How this connects to the broader research picture
This review sits alongside the July 2026 Yale/JAMA secret shopper study on telehealth GLP-1 prescribing oversight as a second, related data point: one shows prescribing access has outpaced clinical screening at many platforms; this one shows post-prescription clinical support — specifically nutritional guidance — is inconsistently built into GLP-1 treatment programs generally.[3] Neither study is about the medications' efficacy, which remains well-established for weight loss; both are about the infrastructure surrounding how that efficacy gets delivered in practice.
Compare providers that include nutritional support
Source GLP-1 tracks which providers build dietitian access into their programs.